PRINCETON, N.J., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 9:30 AM PT (12:30 PM ET) on Thursday, January 15th, 2015.
A live webcast of this presentation may be accessed through the Company's web site at www.agiletherapeutics.com, on the "Events and Presentations" page. An archived version of the presentations will be available on the web site for 30 days.
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
CONTACT: Mary Coleman 609-683-1880Source:Agile Therapeutics